The planned registration program consists of two double-blind, placebo-controlled multicenter Phase 3 trials, FASCINATE-3 and FASCINIT, to evaluate the safety...
Adds Proven Kidney-on-Chip Technology to Its Pioneering Bio-AI PlatformBOSTON and TEL AVIV, Israel, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Quris-AI...
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics...
Investments will support new product offerings, US expansion, and development of pathology foundation models. BERLIN and NEW YORK, Oct. 29,...
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release...
VANCOUVER, BC / ACCESSWIRE / October 29, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased...
URAC accreditation reflects Capital Rx's commitment to achieving and maintaining the highest quality, member engagement and experience, and operational standards...
Amalia Adler-Waxman, SVP, Head of Sustainability at TevaNORTHAMPTON, MA / ACCESSWIRE / October 28, 2024 / Teva Pharmaceutical My name...
Houston, Texas--(Newsfile Corp. - October 28, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) trading on the OTC Markets under the...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company...
Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be Presented at...
ZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
FREDERICK, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI” or the “Company”) (NASDAQ: TOMZ), a global...
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumabBASKING RIDGE, N.J., Oct....
Robin Kramer, Chief Accounting Officer, to Succeed HimCAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today...
STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizationsLAVAL, QC / ACCESSWIRE / October 27, 2024 /...
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate...
Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints...
Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS...